Treatment options for

metastatic urothelial carcinoma:

eLearning activities

Publication date: 11 May 2022

Accreditation expiration date: 11 May 2023

Estimated time to complete: 15 minutes

Activity 2: Immunotherapy in advanced urothelial cancer: second-line and beyond

In this eLearning video module, Simon Chowdhury will explain the standard of care with immunotherapy in second- and subsequent treatment lines, reviewing potential factors that can influence treatment decisions in these settings.

Learning objectives

After completing this activity, you will be able to:

Discuss available immunotherapy options for second-line (and beyond) in patients with mUC
Interpret clinical data behind new immunotherapy options for patients whose disease have progressed after first-line therapy
Identify the best treatment strategy based on individual patient characteristics

Login to access this activity

No account? Create a free account now

Email*
Password*
Enter Password Confirm Password
Healthcare Professional*
(Required) I confirm that I am a healthcare professional*
Privacy Acceptance*
(Required) I have read and accept the terms of the Privacy notice and the Terms and Conditions and consent to receive e-alerts from Springer Healthcare IME pertinent to my area of interest. I can withdraw my consent at any time by contacting IME@springer.com or via the ‘unsubscribe’ link included in any email communications*
SHE Communication Preferences
(Optional) I agree that my email address will be used by our sister site Medicine Matters Oncology, as per their Privacy Policy, for the purposes of communicating to me details of educational content pertinent to Oncology. I can withdraw my consent at any time by contacting medicinematters@springer.com or via the ‘unsubscribe’ link included in any email communications.
Comments
This field is for validation purposes and should be left unchanged.

Module Content

Sections Status